Menu Search
Equities

Zevra Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ZVRA:NSQ

Zevra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.50
  • Today's Change0.10 / 1.19%
  • Shares traded33.00
  • 1 Year change+6.38%
  • Beta0.9274
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Zevra Therapeutics Inc's revenues fell -14.02% from 27.46m to 23.61m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 46.05m to a larger loss of 105.51m.
Gross margin93.88%
Net profit margin41.86%
Operating margin-103.89%
Return on assets15.30%
Return on equity34.81%
Return on investment17.62%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Zevra Therapeutics Inc fell by 9.26m. Cash Flow from Financing totalled 82.11m or 347.74% of revenues. In addition the company used 69.67m for operations while cash used for investing totalled 22.16m.
Cash flow per share0.7399
Price/Cash flow per share11.77
Book value per share2.37
Tangible book value per share2.17
More ▼

Balance sheet in USDView more

Zevra Therapeutics Inc has a Debt to Total Capital ratio of 31.53%, a lower figure than the previous year's 84.43%.
Current ratio8.62
Quick ratio8.57
Total debt/total equity0.4604
Total debt/total capital0.3153
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.